Drug
Gsk2402968
Gsk2402968: highest development phase Phase 3, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK2402968 NCT01480245 | Phase 3 | Muscular Dystrophies |
Latest
No recent events.
Follow Gsk2402968 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.